Alkermes brings opioid dependence treatment into Phase 3

By Mass High Tech Staff

ACT readies for IND of stem-cell-based eye therapy [March 12, 2009]

PSivida posts positive results from eye implant study [March 12, 2009]

Biopure is running out of cash, seeks options [February 17, 2009]

Nasdaq gives Biopure a break from enforcing trading compliance [December 31, 2008]

Cambridge biotech firm Alkermes Inc. has begun a Phase 3 clinical trial of its Vivitrol long-term treatment for opioid dependence, the company reports.

Using 200 opioid-dependent patients, the clinical study will test the safety of the treatment for the chronic brain disease, with the goal of filling out a supplemental New Drug Application for the U.S. Food and Drug Administration.

Vivitrol got FDA approval in April 2006 as a treatment for alcohol dependence.

Elliot Ehrich, Alkerme’s chief medical officer, called it the only non-addictive, non-narcotic and long-lasting opioid dependency treatment.

Alkermes reported net income of $9.5 million for 2007 on revenue of $239.97 million. The firm produces treatments for alcohol dependence and schizophrenia.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.